Toll Free: 1-888-928-9744

Pertussis - Pipeline Review, H2 2015

Published: Oct 21, 2015 | Pages: 98 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pertussis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Pertussis - Pipeline Review, H2 2015', provides an overview of the Pertussis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pertussis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pertussis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents
2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pertussis Overview 10 Therapeutics Development 11 Pipeline Products for Pertussis - Overview 11 Pipeline Products for Pertussis - Comparative Analysis 12 Pertussis - Therapeutics under Development by Companies 13 Pertussis - Therapeutics under Investigation by Universities/Institutes 15 Pertussis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pertussis - Products under Development by Companies 19 Pertussis - Products under Investigation by Universities/Institutes 21 Pertussis - Companies Involved in Therapeutics Development 22 Beijing Minhai Biotechnology Co., Ltd 22 Beijing Tiantan Biological Products Co., Ltd. 23 Bharat Biotech International Limited 24 Biological E. Limited 25 Boryung Pharmaceutical Co., Ltd. 26 Daiichi Sankyo Company, Limited 27 DBV Technologies S.A. 28 GlaxoSmithKline Plc 29 Green Cross Corporation 30 Immunovaccine, Inc. 31 Indian Immunologicals Limited 32 LG Life Sciences Limited 33 NanoBio Corporation 34 Panacea Biotec Limited 35 Sanofi 36 Sanofi Pasteur SA 37 Serum Institute of India Limited 38 Sinovac Biotech Ltd. 39 Synthetic Biologics, Inc. 40 Zydus Cadila Healthcare Limited 41 Pertussis - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 (diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 (diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B]) vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 (diphtheria + tetanus + pertussis (whole-cell)) vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 (diphtheria + tetanus + pertussis) vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 diphtheria + tetanus+ pertussis (whole cell) vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 GC-3111A - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 pertussis (acellular) vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 pertussis (acellular) vaccine - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 pertussis (acellular) vaccine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 pertussis (acellular) vaccine - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 pertussis (whole-cell) vaccine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pertussis + hepatitis B vaccine - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 pertussis vaccine - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pertussis vaccine - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pertussis vaccine - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 PR-5I - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Recombinant BCG - Pertussis Vaccine - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SYN-005 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 VN-0103 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Pertussis - Recent Pipeline Updates 86 Pertussis - Dormant Projects 88 Pertussis - Discontinued Products 89 Pertussis - Product Development Milestones 90 Featured News & Press Releases 90 Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis) 90 Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 91 Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 91 Oct 16, 2014: BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014 92 Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 92 Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program 93 Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 93 Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 94 Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 95 Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 95 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 97 Disclaimer 98
List of Tables
Number of Products under Development for Pertussis, H2 2015 11 Number of Products under Development for Pertussis - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Late Stage Development, H2 2015 16 Comparative Analysis by Clinical Stage Development, H2 2015 17 Comparative Analysis by Early Stage Development, H2 2015 18 Products under Development by Companies, H2 2015 19 Products under Development by Companies, H2 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2015 21 Pertussis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 22 Pertussis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015 23 Pertussis - Pipeline by Bharat Biotech International Limited, H2 2015 24 Pertussis - Pipeline by Biological E. Limited, H2 2015 25 Pertussis - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015 26 Pertussis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 27 Pertussis - Pipeline by DBV Technologies S.A., H2 2015 28 Pertussis - Pipeline by GlaxoSmithKline Plc, H2 2015 29 Pertussis - Pipeline by Green Cross Corporation, H2 2015 30 Pertussis - Pipeline by Immunovaccine, Inc., H2 2015 31 Pertussis - Pipeline by Indian Immunologicals Limited, H2 2015 32 Pertussis - Pipeline by LG Life Sciences Limited, H2 2015 33 Pertussis - Pipeline by NanoBio Corporation, H2 2015 34 Pertussis - Pipeline by Panacea Biotec Limited, H2 2015 35 Pertussis - Pipeline by Sanofi, H2 2015 36 Pertussis - Pipeline by Sanofi Pasteur SA, H2 2015 37 Pertussis - Pipeline by Serum Institute of India Limited, H2 2015 38 Pertussis - Pipeline by Sinovac Biotech Ltd., H2 2015 39 Pertussis - Pipeline by Synthetic Biologics, Inc., H2 2015 40 Pertussis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 41 Assessment by Monotherapy Products, H2 2015 42 Assessment by Combination Products, H2 2015 43 Number of Products by Stage and Target, H2 2015 45 Number of Products by Stage and Route of Administration, H2 2015 47 Number of Products by Stage and Molecule Type, H2 2015 49 Pertussis Therapeutics - Recent Pipeline Updates, H2 2015 86 Pertussis - Dormant Projects, H2 2015 88 Pertussis - Discontinued Products, H2 2015 89


List of Figures
Number of Products under Development for Pertussis, H2 2015 11 Number of Products under Development for Pertussis - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 13 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Late Stage Development, H2 2015 16 Comparative Analysis by Clinical Stage Development, H2 2015 17 Comparative Analysis by Early Stage Products, H2 2015 18 Assessment by Monotherapy Products, H2 2015 42 Assessment by Combination Products, H2 2015 43 Number of Products by Top 10 Targets, H2 2015 44 Number of Products by Stage and Top 10 Targets, H2 2015 44 Number of Products by Top 10 Routes of Administration, H2 2015 46 Number of Products by Stage and Top 10 Routes of Administration, H2 2015 46 Number of Products by Top 10 Molecule Types, H2 2015 48 Number of Products by Stage and Top 10 Molecule Types, H2 2015 48

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify